LOXL2 and neoplasm: These results suggest that serum sEV LOXL2 can reflect a hypoxic and aggressive tumor type and that serum sEV-LOXL2 levels could serve as an alternative to tissue LOXL2 as an independent prognostic factor of overall survival for patients with HNSCC.